The Silverstein Foundation for Parkinson's With Gba
Historical funder research: IRS Form 990-PF filings from US private foundations, showing who funded what in past years. This is not a list of currently open grant calls, and we do not track open RFPs from private foundations. From public IRS Form 990-PF filings (latest on file for this funder: tax year 2024). Coverage: tax years 2019–2025. Freshness: the IRS releases these returns 1.5–2+ years after the tax year ends, so 2025 is still partial and a funder's newest grants may not appear yet. Last updated: November 14, 2026. Filings can contain errors, so confirm current priorities and deadlines with the funder before applying.
Year 2025 is still partial because many returns have not been filed or released yet. That is a freshness issue — coverage in our dataset is tax years 2019–2025.
Only 30.0% of this funder's organizational grants could be linked to an IRS cause code.
- Form & materials
- THE FOUNDATION'S BOARD OF TRUSTEES AND SCIENTIFIC ADVISORY COMMITTEE ACCEPT GRANT APPLICATIONS FROM ORGANIZATIONS FOCUSED ON RAPIDLY CONVERTING SCIENTIFIC IDEAS AND EXPERIMENTAL DRUGS INTO FDA APPROVED THERAPEUTICS TO TREAT AND PREVENT THE ONSET OF PARKINSON'S DISEASE IN GBA-MUTATION CARRIERS.
- Deadlines
- THE FOUNDATION REVIEWS QUALIFIED GRANT APPLICATIONS AS RECEIVED.
- Restrictions
- NONE
| Recipient | Location | Purpose (as filed) | Amount | Tax yr |
|---|---|---|---|---|
| Baylor College of Medicine | Huston, TX | THE SILVERSTEIN FELLOWSHIP. | $75,000 | 2024 |
| The New York STEM Cell Foundation | New York, NY | DRUG DISCOVERY FOR PARKINSON'S WITH GBA | $627,500 | 2023 |
| Tel Aviv Sourasky Medical Center | Tel Avivyafo, Israel | THE ROLE OF THE IMMUNE SYSTEM IN GLUOCEREBROSIDASE (GBA)-PD: A CSF AND PBMC STUDY | $276,000 | 2023 |
| Sunnybrook Research Institute | Toronto, Canada | A PHASE I/II STUDY FOR BILATERAL PUTAMENAL DELIVERY OF RECOMBINANT GLUCOCEREBROSIDASE IN PATIENTS WITH PARKINSON'S DISEASE USING MR-GUIDED FOCUSED ULTRASOUND INDUCED OPENING OF THE BLOOD-BRAIN BARRIER | $250,000 | 2023 |
| Curasen Therapeutics | San Carlos, CA | GENOTYPING AND BIOMARKER ANALYSES IN CLINICAL STUDY | $225,000 | 2023 |
| The Chancellor Masters and Scholars of the University of Oxford | Oxford, United Kingdom | SUPPORT ONE MOVEMENT DISORDERS FELLOW FOR A TWO-YEAR PERIOD WHO HAS A FOCUS ON GBA-PARKINSON'S DISEASE RESEARCH AND/OR CLINICAL DEVELOPMENT | $195,000 | 2023 |
| Hamad Bin Khalifa University | Arrayyan, Qatar | THERAPEUTIC NANOBODY DEVELOPMENT FOR TARGETING ALPHA-SYNUCLEIN AGGREGATION IN PARKINSON'S DISEASE, WITH FOCUS ON PARKINSON'S DISEASE WITH GBA MUTATION | $190,000 | 2023 |
| The New York STEM Cell Foundation | New York, NY | DRUG DISCOVERY FOR PARKINSON'S WITH GBA. | $1,372,500 | 2022 |
| Lysoway Therapeutics | Cambridge, MA | EVALUATING THE THERAPEUTIC EFFECTS OF TRPML1 AND TMEM175 AGONISTS ON GBA-DEFICIENT PARKINSON'S DISEASE MODELS. | $225,000 | 2022 |
| Michael J Fox Foundation Modag | New York, NY | FOLLOW-UP STUDY OF A DRUG (ANLE138B) - GOAL IS TO STOP THE PARKINSON'S PROTEIN ALPHA-SYNUCLEIN (A-SYN) FROM CLUMPING TOGETHER. | $200,000 | 2022 |
Grants to individuals are counted but not named.
The free funder search finds foundations that funded organizations like your client's, by cause and location. Free templates: multi-client grant calendar, grant tracker. GrantCorral is a workspace for grant consultants with several clients; founding members get 60 days free on Consultant, no card required, then 50% off the first year if they stay.